Clinical trials: Head and Neck Squamous Cell Carcinomas
Squamous Cell Carcinoma of the Head and Neck
Trial of 2 Cycles of Induction Chemo With Abraxane, Cetuximab, Cisplatin, & 5-FU for Advanced Head and Neck Cancer
This phase two trial will determine the tumor response rate at the primary site and at involved regional nodes to two cycles of an IC regimen of weekly Abraxane and cetuximab given in combination with cisplatin and 5-FU in…
- Trial name
- NCT00736944
- Testing
- Abraxane, Cetuximab, Cisplatin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Washington University School of Medicine
Oral Squamous Cell Carcinoma, Oral Potentially Malignant Disorder
NBI for Early Diagnosis of OPMD/OSCC
Early detection - possibly at its pre-malignant stages (Oral Potentially Malignant Disorders, OPMD) - with periodic surveillance is thus fundamental for limiting disease burden, hopefully reducing the incidence of advanced stages…
- Trial name
- NBI_Oral (NCT06438939)
- Testing
- Biopsy for diagnostical purposes
- Where
- Italy
- Volunteers
- 480 people
- Sponsor
- Cardarelli Hospital
Esophageal Cancer
Adjuvant Durvalumab for Esophageal Cancer
Adjuvant Durvalumab vs Placebo for 1 year after complete resection of esophageal cancer following neoadjuvant CCRT.
- Trial name
- NCT02520453
- Testing
- Durvalumab
- Where
- South Korea
- Volunteers
- 86 people
- Sponsor
- Samsung Medical Center
Carcinoma, Squamous Cell of Head and Neck (HNSCC), Melanoma
A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab
This study is open to adults with advanced head and neck cancer, skin cancer, or non-small cell lung cancer. People can take part if previous treatments were not successful.
- Conditions
- Carcinoma, Squamous Cell of Head and Neck (HNSCC), Melanoma, Non-small Cell Lung Cancer (NSCLC)
- Trial name
- NCT05068102
- Testing
- BI 765063, Ezabenlimab, [89Zr]Zr- BI 765063
- Where
- Netherlands
- Volunteers
- 14 people
- Sponsor
- Boehringer Ingelheim
Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
Evaluating the Use of Dual Imaging Techniques for Detection of Disease in Patients With Head and Neck Cancer
This phase I trial evaluates the safety and effectiveness of using two imaging techniques, indium In 111 panitumumab (111In-panitumumab) with single photon emission computed tomography (SPECT)/computed tomography (CT) and…
- Trial name
- NCT05945875
- Testing
- Panitumumab-IRDye800, Indium In 111 Panitumumab, Single Photon Emission Computed Tomography
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Laryngeal Verrucous Carcinoma
Interstitial Photodynamic Therapy in Treating Patients With Recurrent Head and Neck Cancer
This phase II trial studies the effects of interstitial photodynamic therapy in patients with head and neck cancer that has come back.
- Conditions
- Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Laryngeal Verrucous Carcinoma, Recurrent Lip and Oral Cavity Squamous Cell Carcinoma, Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary
- Trial name
- NCT02068157
- Testing
- Laboratory Biomarker Analysis, Photodynamic Therapy, Porfimer Sodium
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Roswell Park Cancer Institute
Squamous Cell Carcinoma, Laryngeal Cancer
Observational Study of Swallowing Function After Treatment of Advanced Laryngeal Cancer
The purpose of this prospective, multi-institutional, observational cohort study is to determine if an initial surgical approach leads to better function and quality of life than primary chemoradiation in a subset of patients…
- Trial name
- NCT01089803
- Where
- United States
- Volunteers
- 279 people
- Sponsor
- University of Minnesota
Squamous Cell Carcinoma of Head and Neck
Pembrolizumab Plus Olaparib in LA-HNSCC
The purpose of this research study is to evaluate the effectiveness of using a combination of pembrolizumab and olaparib when given before and after standard chemoradiation therapy in treating locally advanced head and neck…
- Trial name
- NCT05366166
- Testing
- Pembrolizumab, Olaparib, Cisplatin
- Where
- 4 sites in United States
- Volunteers
- 45 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Esophageal Cancer
ESI With EUS to Differentiate T3 and T4 ESCC
By using a novel technique of extraesophageal saline injection (ESI),the esophagus is to be separate from the adjacent organs.The space between esophagus and adjacent organs can be detected by endoscopic ultrasonography enhanced…
- Trial name
- ESI (NCT01930630)
- Testing
- Extraesophageal saline injection (ESI)
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Sun Yat-sen University
Metastatic or Recurrent Squamous Cell Carcinoma of the Esophagus
Lapatinib (GW572016) for Metastatic or Recurrent Squamous Cell Carcinoma Esophagus
The purpose of this study is the determine whether a new compound, called lapatinib, can be effective in shrinking cancerous tumors of the esophagus that have recurred or spread somewhere else in the body.
- Trial name
- NCT00239200
- Testing
- Lapatinib
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of Michigan Rogel Cancer Center
Squamous Cell Carcinoma of Oropharynx
Treatment De-Intensification for Squamous Cell Carcinoma of the Oropharynx
This research is being done to try to reduce radiation side effects that happen with the standard radiation methods. Generally surgery, radiation therapy, and sometimes chemotherapy are standard treatment for people with squamous…
- Trial name
- NCT01088802
- Testing
- IMRT, Cisplatin, Carboplatin
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Head and Neck Squamous Cell Carcinoma
FID-007 Followed by Standard of Care Surgery in Head and Neck Cancer
This phase I trial studies on how the PEOX-based polymer encapsulated paclitaxel FID-007 (FID-007) affects the immune cells around the tumor patients with head and neck squamous cell carcinoma.
- Trial name
- NCT06338657
- Testing
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- University of Southern California
HNSCC, Lysogenic HSV Virus
A Clinical Study on Neoadjuvant Treatment of Resectable Head and Neck Squamous Carcinoma With Immune-targeted Therapy and Lysogenic HSV Virus
Evaluation of the safety and tolerability of immune-targeted therapy combined with neoadjuvant therapy with lysogenic HSV virus for patients with surgically resectable squamous carcinoma of the head and neck.
- Conditions
- HNSCC, Lysogenic HSV Virus, Neoadjuvant Therapy, Immunotherapy
- Trial name
- NCT06741982
- Testing
- Lysogenic HSV virus., Tislelizumab, Afatinib
- Where
- China
- Sponsor
- West China Hospital
HNSCC
Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC
Open-label, Phase II, randomized, controlled study evaluating the efficacy and safety of danvatirsen in combination with pembrolizumab compared with pembrolizumab alone as first-line treatment of patients with…
- Trial name
- PEMDA-HN (NCT05814666)
- Testing
- Danvatirsen, Pembrolizumab
- Where
- 32 sites in United States, South Korea and 1 more
- Volunteers
- 69 people
- Sponsor
- Flamingo Therapeutics NV
Hepatocellular Carcinoma, Metastatic Castration Resistant Prostate Cancer
TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers
This is a phase 1/1b open label, multicenter dose escalation and dose expansion study to investigate the safety, tolerability and anti-tumor activity of TPST-1120, a small molecule selective antagonist of PPARα (peroxisome…
- Conditions
- Hepatocellular Carcinoma, Metastatic Castration Resistant Prostate Cancer, Renal Cell Carcinoma, Non-small Cell Lung Cancer
- Trial name
- NCT03829436
- Testing
- Part 1 TPST-1120, Part 2 TPST-1120 + nivolumab, Part 3 TPST-1120
- Where
- 11 sites in United States
- Volunteers
- 38 people
- Sponsor
- Tempest Therapeutics
Esophageal Cancer
Circulating Tumor DNA MRD-Guided Adjuvant Therapy for Curatively Resected Locally Advanced Esophageal Squamous Cell Carcinoma
This study was a multicenter, randomized, phase 3 trial to determine whether adjuvant chemotherapy including tisleliizumab improves recurrence-free survival compared to follow-up alone without chemotherapy in patients with…
- Trial name
- MRD2START (NCT06914011)
- Testing
- Tislelizumab
- Volunteers
- 172 people
- Sponsor
- Asan Medical Center
Head and Neck Squamous Cell Carcinoma HNSCC
[68Ga]Ga-FAPI-46 in Staging of Head and Neck Carcinomas
The trial focuses on assessing the role of [68Ga]Ga-FAPI-46 in head and neck squamous cell carcinomas (HNSCC) staging before surgery.
- Trial name
- FAPIHN (NCT06794372)
- Testing
- [68Ga]Ga-FAPI-46 PET/CT
- Where
- Switzerland
- Volunteers
- 20 people
- Sponsor
- John O. Prior
Early-Stage Oral Squamous Cell Carcinoma
Neoadjuvant Low-Dose Radiotherapy Combined With Adebrelimab and Single-Agent Albumin-Bound Paclitaxel Chemotherapy for Early-Stage Oral Squamous Cell Carcinoma: A Prospective, Single-Arm Clinical Trial
This is a prospective, single-arm, Phase II clinical trial. The included population consisted of untreated patients with histologically confirmed stage I-II oral squamous cell carcinoma.
- Trial name
- NCT07007364
- Testing
- Adebrelimab Combined With Albumin Paclitaxel
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Jun Jia
Immunotherapy, Cancer
Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform (ELEPHAS-02)
The primary objective of this study is to develop and train the Elephas live tumor diagnostic platform and determine the ex-vivo accuracy of the Elephas Score using in-vivo RECIST 1.1 as the reference method
- Conditions
- Immunotherapy, Cancer, Bladder Cancer, Urothelial Carcinoma Bladder
- Trial name
- ELEPHAS-02 (NCT05520099)
- Testing
- Core Needle Biopsy, Forceps Biopsy, Punch Biopsy
- Where
- 12 sites in United States
- Volunteers
- 416 people
- Sponsor
- Elephas
Carcinoma, Squamous Cell of Head and Neck, Carcinoma, Non-Small-Cell Lung
Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors
This is an open-label, multicenter, phase I study to evaluate the safety and tolerability of durvalumab ± tremelimumab in combination with chemoradiation in patients with advanced solid tumors
- Conditions
- Carcinoma, Squamous Cell of Head and Neck, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma
- Trial name
- CLOVER (NCT03509012)
- Testing
- Durvalumab, Tremelimumab, Cisplatin (dose level 4)
- Where
- 16 sites in United States, Japan and 3 more
- Volunteers
- 105 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.